The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

Younak Choi; Tae-Yong Kim; Do-Youn Oh; Kyung-Hun Lee; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang

doi:10.4143/crt.2014.292

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(1); 2016 > Article

Original Article The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy: Younak Choi, MD¹, Tae-Yong Kim, MD^1,2, Do-Youn Oh, MD, PhD^1,2,, Kyung-Hun Lee, MD^1,2, Sae-Won Han, MD, PhD^1,2, Seock-Ah Im, MD, PhD^1,2, Tae-You Kim, MD, PhD^1,2, Yung-Jue Bang, MD, PhD^1,2; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(1):171-179.
DOI: https://doi.org/10.4143/crt.2014.292
Published online: March 13, 2015

¹Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea

Correspondence: Do-Youn Oh, MD, PhD Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea
Tel: 82-2-2072-0701 Fax: 82-2-762-9662 E-mail: ohdoyoun@snu.ac.kr

• Received: October 18, 2014 • Accepted: February 2, 2015

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

16,494 Views
136 Download
47 Web of Science
50 Crossref
54 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
A causal relationship between diabetes mellitus (DM) and pancreatic cancer is well established. However, in patients with advanced pancreatic cancer (APC) who receive palliative chemotherapy, the impact of DM on the prognosis of APC is unclear.
Materials and Methods
We retrospectively enrolled APC patients who received palliative chemotherapy between 2003 and 2010. The patients were stratified according to the status of DM, in accordance with 2010 DM criteria (American Heart Association/American Diabetes Association). DM at least 2 years’ duration prior to diagnosis of APC was defined as remote-onset DM (vs. recent-onset).
Results
Of the 349 APC patients, 183 (52.4%) had DM. Among the patients with DM, 160 patients had DM at the time of diagnosis of APC (remote-onset, 87; recent-onset, 73) and the remaining 23 patients developed DM during treatment of APC. Ultimately, 73.2% of patients (134/183) with DM received antidiabetic medication, including metformin (56 patients, 41.8%), sulfonylurea (62, 45.5%), and insulin (43, 32.1%). In multivariate analysis, cancer extent (hazard ratio [HR], 1.792; 95% confidence interval [CI], 1.313 to 2.445; p < 0.001) showed association with decreased overall survival (OS), whereas a diagnosis of DM (HR, 0.788; 95% CI, 0.615 to 1.009; p=0.059) conferred positive tendency on the OS. Metformin treatment itself conferred better OS in comparison within DM patients (HR 0.693; 95% CI, 0.492 to 0.977; p=0.036) and even in all APC patients (adjusted HR, 0.697; 95% CI, 0.491 to 1.990; p=0.044).
Conclusion
For APC patients receiving palliative chemotherapy, metformin treatment is associated with longer OS. Patients with DM tend to survive longer than those without DM.
Key words: Pancreatic neoplasms, Prognosis, Antineoplastic agents, Diabetes mellitus, Metformin

Introduction

Pancreatic cancer (PC) is the fourth common cause of cancer death in both Asian and western countries [1]. At the time of diagnosis, only 10%-20% of patients are eligible for curative surgery. PC is an aggressive malignancy with a 5-year survival rate < 5% [2].

Diabetes mellitus (DM) is linked as a risk factor in a number of cancers [3]. Although the mechanisms of increased incidence of cancer with DM are not fully understood, insulin resistance, leading to hyperinsulinemia, causes up-regulation of insulin-like growth factor-I (IGF-I) signaling pathway to increase proliferation and invasion of cancer cells and decrease apoptosis [4,5].

Previous studies have shown that recent-onset DM has increased the risk of PC [6,7]. Some studies have even suggested that recent-onset DM could be used as a biomarker of asymptomatic early PC [8]. Although there is some controversy regarding whether DM predisposes to PC or is simply a consequence thereof, there is increasing evidence for recent-onset DM as an early manifestation of PC and for the long standing DM as a risk factor of PC with twice the incidence [9].

The utility of DM as a prognostic index in PC is a matter of debate. In two previous studies where patients with resectable and unresectable PC were grouped together, the survival was shortened for those with DM [10,11]. A retrospective review, limited to resectable PC, also showed that survival in patients with DM (especially recent-onset DM) was shortened [12]. Another retrospective study with 540 patients with any stage of PC reported that patients with DM alone without other constitutional symptoms such as pain, jaundice, and appetite loss had better survival than symptomatic patients [13]. However, for patients with unresectable PC receiving palliative chemotherapy, the prognostic value of DM has rarely been addressed despite the fact that this population constitutes the majority (approximately 80%) of patients with PC.

Recently, metformin, a widely used antidiabetic drug, has received attention for its anti-neoplastic role. Recent epidemiologic evidence is in favor of its protective role against PC [14] and of its beneficial roll in non-metastatic disease [15].

Therefore, we investigated whether DM and metformin have any association with survival of advanced PC (APC) patients undergoing palliative chemotherapy.

Materials and Methods

Consecutive patients with APC, confirmed by histology and all recipients of palliative chemotherapy from January 2003 to June 2010, were enrolled in this study.

1. Data collection and categorization

Precisely defined DM disease status was a requirement, stipulated as follows: (1) self-reported diabetic history; (2) ongoing treatment with antidiabetic medication(s); or (3) qualification as DM during the follow-up period, based on 2010 American Heart Association/American Diabetes Association (AHA/ADA) joint criteria.

Each patient’s medical records were reviewed retrospectively. Date of diagnosis was the date that locally advanced PC (LAPC) or metastatic/recurrent PC (MPC) was confirmed. Patient age, performance status, DM status, antidiabetic treatments, body weight, body mass index (BMI), smoking history, and initial laboratory data were assessed.

For our purposes, we subdivided DM by onset and duration, designating diagnosis within 2 years prior to confirmed APC as “recent-onset DM,” and diagnosis > 2 years prior to confirmed APC as “remote-onset DM.” In addition, “preexisting DM” indicated diagnosis of DM before or at the time APC was confirmed (i.e., both “recent-onset” and “remote-onset” DM subsets) and “subsequent DM” corresponded with DM diagnosed after confirmation of APC. “Concurrent DM” incorporated both “preexisting” and “subsequent” subsets of DM.

Body weight and BMI at the time of initiation of palliative chemotherapy were cited as “initial weight” and “initial BMI.” “Initial weight loss” was the weight change experienced at the time of APC diagnosis, using a prior healthy state as reference. BMI was calculated individually as body weight divided by square of height (kg/m²). Patients were then stratified by BMI (< 22.5, 22.5-24.9, and ≥ 25.0), given the known association of BMI with mortality in Asians [16].

2. Statistical analysis

The study endpoint is overall survival (OS) defined as the period from diagnosis of APC to death from any cause. We calculated median OS using the Kaplan-Meier method. Between-group differences in demographic and clinical data were evaluated using Fisher exact test for categorical variables. For the effect of multiple factors on survival, the hazard ratio (HR) and its 95% confidence interval (CI) were evaluated using Cox proportional hazards model. The survival of the two groups was compared using the log-rank test. All tests were 2-sided, and p-values of ≤ 0.05 were considered statistically significant. We performed statistical analyses using SPSS ver. 19.0 (IBM Co., Armonk, NY).

This study was reviewed and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. H-1102-023-350). All studies were conducted according to guidelines (Declaration of Helsinki) for biomedical research.

Results

1. Patient characteristics

A total of 349 patients were enrolled. By definition, 183 patients (52.4%) had concurrent DM, whether preexisting (160 patients) or subsequent (23 patients). Of those with preexisting DM, 87 qualified as remote-onset and 73 as recent-onset. The majority of patients with concurrent DM (134/183, 73.2%) were taking antidiabetic medication, including metformin (56/134, 41.8%), sulfonylurea (62/134, 45.5%), and insulin (43/134, 32.1%) (Table 1). Median age of patients was 59.6 years and 64.2% were male. Sixty-six patients (18.9%) were diagnosed as LAPC and 283 patients (81.1%) as MPC. Four of every five subjects had good Eastern Cooperative Oncology Group performance status (0-1). Distribution of BMI was initially biased towards low (< 22.5 kg/m², 62.0%; 22.5-24.9 kg/m², 25.8%; ≥ 25.0 kg/m², 12.2%) and one of every three patients (33.1%) suffered weight loss during the first-line chemotherapy. As a first-line chemotherapy, 324 patients (92.8%) received gemcitabine containing regimens and 53 patients (15.2%) were treated with gemcitabine or fluorouracil based concurrent chemoradiotherapy. Overall, 197 patients (56.4%) achieved favorable responses (complete response, partial response, and stable disease) to first-line palliative chemotherapy (Table 2).

Median duration of follow-up for all patients was 10.2 months (95% CI, 9.3 to 11.1 months), and median OS was 7.9 months (95% CI, 7.0 to 8.8 months). One-year and 2-year survival rates were 31% and 8%, respectively.

2. Determinants of prognosis for all patients

In univariate analysis, Eastern Cooperative Oncology Group performance status (ECOG PS) (p=0.013), cancer extent (p < 0.001), concurrent DM (p=0.041), and weight loss during chemotherapy (p=0.026) significantly impacted OS (Table 3). In multivariate analysis, cancer extent/metastasis (HR, 1.792; 95% CI, 1.313 to 2.445; p < 0.001) conferred a higher risk of death, whereas concurrent DM (HR, 0.788; 95% CI, 0.615 to 1.009; p=0.059) showed the tendency of lowering risk.

3. Patient comparisons (DM vs. non-DM)

The OS of the DM group was 8.4 months (95% CI, 6.8 to 10.0 months), compared with 7.5 months (95% CI, 6.3 to 8.7 months) for the non-DM group (p=0.041, log-rank test) (Fig. 1). The clinical characteristics of patients with APC were also compared in order to determine other factors causing the difference of OS between DM and non-DM subsets (Table 2). In the DM group, more patients were past the age of 60 years than in the non-DM group (59.6% vs. 38.0%, p < 0.001). ECOG PS, cancer extent, cancer antigen 19-9 level, and response to chemotherapy, etc. did not differ significantly between groups, although patients with DM showed a tendency for greater weight loss at diagnosis (change in BMI ≥ 1, p=0.067).

4. Analysis of OS in DM group

More than half of our cohort had DM. When stratified as remote- or recent-onset DM, the clinical characteristics by subset were similar, except for more liberal use of antidiabetic medication in patients with remote-onset DM (p=0.002) (Supplementary Table 1). Metformin usage did not differ for remote-onset DM (32.2%) and recent-onset DM (34.2%), but insulin was more often used for remote-onset DM (34.5% vs. 17.8%, p=0.001).

Recent-onset DM did not have significantly prolonged OS, compared with remote-onset/subsequent DM (7.9 months vs. 9.8 months; HR, 0.789; 95% CI, 0.574 to 1.083; p=0.142) (Table 4, Fig. 2A). Neither antidiabetic medication in general nor sulfonylurea or insulin specifically affected OS in DM patients. However, recipients of metformin survived longer than non-recipients (HR, 0.693; 95% CI, 0.492 to 0.977; p=0.036) (Table 4, Fig. 2B). However, recipients and non-recipients of metformin had similar clinical characteristics (Supplementary Table 2).

5. Analysis of OS in all patients, relative to metformin use

Focusing on metformin treatment, we reanalyzed prognostic indices of APC for the entire cohort, including non-DM patients (Table 5). The OS of metformin-treated patients was significantly longer than that of all other groups. Relative to the APC cohort overall, metformin treatment conferred better survival as well (11.0 months vs. 7.8 months; adjusted HR, 0.697; 95% CI, 0.491 to 1.990; p=0.044), given similar baseline clinical characteristics (Fig. 3A, Supplementary Table 3). OS of metformin-treated DM patients was also significantly longer than that of all other groups, respectively (non-DM or DM without metformin, p=0.029) (Fig. 3B).

Discussion

In this study, we confirmed the possibility of metformin as an independent prognostic factor for APC patients undergoing palliative chemotherapy. Although we could not prove the association of DM with survival, we were able to show that APC patients with DM tend to survive longer than those without DM.

Metformin is an oral biguanide widely used as a single and combination therapy for DM. Many clinical data have proven the biological mechanisms of metformin as a glucose-lowering agent and an anticancer drug at a cellular level. Growth inhibition through metabolic pathways of metformin is associated with activation of AMP-activated protein kinase (AMPK) via the serine-threonine liver kinase B1 (LKB1), which in turn decreases the phosphorylation of mammalian target of rapamycin (mTOR) and S6 kinase and then results in reducing mRNA translation and protein synthesis [17]. More recent studies have reported on the persisting effects of metformin with several AMPK-independent mechanisms, such as inhibition of IGF-1 receptor signaling through downstream pathways that include extracellular signal-regulated kinase and mTOR, reduction of cAMP level that suppresses protein kinase A activity, or induction of p53-dependent REDD1 expression that leads to mTOR inhibition and cell-cycle arrest in combination with decrease in cyclin D1 expression and pRb phosphorylation and increase in p27 expression. In addition to signaling mechanisms, metformin can also directly scavenge reactive oxygen species (ROS) and block endogenous ROS production [18].

In one case-controlled study, the risk of developing PC among DM patients was reduced with metformin use (odds ratio, 0.38; 95% CI, 0.22 to 0.69; p=0.001), whereas exogenous insulin or an insulin secretagogue actually increased the risk of PC [14]. Another retrospective study of patients with PC (all stages) and DM showed that use of metformin served as a better prognostic index for OS (HR, 0.64; p=0.003). However, the benefit of metformin was not apparent in metastatic PC patients (OS, 8.8 months vs. 7.3 months; p=0.482) [15]. In a recently released study, exposure to metformin had no influence on the prognosis of APC [19].

In our study, 134 patients (73.2% of DM patients) with DM received antidiabetic medication (metformin, 41.8%; sulfonylurea, 45.5%; insulin, 32.1%; other agents, 23.1%). The use of antidiabetic agents as a whole or each of sulfonylurea and insulin showed no association with the prognosis of APC. However, the use of metformin conferred a prognostic benefit on APC patients. The superiority in survival of patients taking metformin was translated to all APC patients as well as within the DM patients (OS, 11.0 months vs. 7.8 months; adjusted HR, 0.697; 95% CI, 0.491 to 1.990; p=0.044) (Fig. 3A), without differences in baseline clinical characteristics (Supplementary Table 3). The metformin-treated DM group had significantly longer survival than the non-DM group or DM without metformin group (p=0.029) (Fig. 3B). Therefore, we concluded that the use of metformin was favorable for prognosis in APC.

Given the difference of primary cancer site, especially the characteristic of pancreas as an organ of insulin secretion, our results have some similarities with those of the recently released analysis of gastric cancer patients who underwent gastrectomy in terms of the decreased mortality rates coupled with increased cumulative use of metformin. In particular, the survival of metformin-treated diabetic patients was not inferior to the survival of non-DM patients in the study [20].

We thought that the recent prospective randomized trials to find the synergism between metformin and chemotherapeutic agents (NCT01210911, NCT01971034, NCT01167738, NCT01666730) could provide us with answers regarding the role of metformin. However, two of them reported that metformin was not beneficial as an add-on therapy to paclitaxel monotherapy or gemcitabine and erlotinib combination therapy. Nevertheless, considering the previous experimental data on the success of metformin with xenograft models, it is still worth waiting for the results of other ongoing trials on metformin in combination with other agents [18].

The prognostic value of duration of DM has rarely been addressed. According to two retrospective studies including resectable PC, one showed shorter OS in recent-onset DM [21], and the other reported increased mortality in long-standing DM (> 5 years) [22]. Recently released meta-analysis from two prospective cohort studies showed decreased survival in long-standing DM (> 4 years) but no difference of survival in recent-onset DM (≤ 4 years), compared with non-DM [23]. In our study, patients with DM tended to survive longer than non-DM patients (HR, 0.788; p=0.059), despite more advanced age (≥ 60 years, p < 0.001). Because there was no difference in survival between the non-DM group and DM without metformin group, we could not exclude the possibility that this advantage of DM patients came from metformin treatment. However, our results showed matched results between the lower HR and extended OS compared to a prior retrospective study which enrolled more LAPC patients than MPC patients and only 6.5% were biguanide users [24]. Some recent studies attempted to interpret PC-related DM with type 3 DM [21], the exogeneous pancreatic failure due to PC, or paraneoplastic syndrome [25] so as to explain better prognosis in DM patients. Due to several limitations in previous studies, including small sample size and small tumor burden, debates regarding the influence of DM on clinical outcomes of APC still remained.

The major limitations of our study originated from the retrospective design. We could not evaluate the duration of antidiabetic medication but we could check whether the patients were taking diabetic medicine during the chemotherapy session. Another drawback is the heterogeneity of antidiabetic medications used. Dual or triple antidiabetic agents, including thiazolidinedione, alpha-glucosidase inhibitor, dipeptidyl peptidase-4 inhibitor, etc., were used simultaneously by more than half the patients. However, the homogeneity of the patient population with advanced disease and good performance status enough for chemotherapy enhances the benefits of our study.

Considering the dearth of research directed at DM and metformin as prognostic factors in APC, we believe that this work represents a significant step forward providing some leverage for patients in addition to palliative chemotherapy.

Conclusion

In conclusion, we have shown that metformin use is a favorable prognostic factor in APC patients receiving palliative chemotherapy. We also showed the tendency that patients with DM survived longer than those without DM. Further studies are warranted to validate the prognostic value of this study, including onset/duration of DM.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2014-292-supple.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Fig. 1.

Overall survival (OS) of all patients by diabetes mellitus (DM) status. Kaplan-Meier estimates, demonstrating positive association between DM and OS (hazard ratio, 0.793; 95% confidence interval, 0.635 to 0.990; p=0.041, log-rank test). mOS, median OS.

Fig. 2.

Overall survival of diabetes mellitus (DM) patients. (A) Recent-onset DM, not having significantly prolonged overall survival (OS) (vs. other DM subsets, including remote-onset DM and subsequent DM; hazard ratio [HR], 0.789; 95% confidence interval [CI], 0.574 to 1.083; p=0.142). (B) OS prolongation in metformin recipients vs non-recipients (HR, 0.693; 95% CI, 0.492 to 0.977; p=0.036). mOS, median OS.

Fig. 3.

Overall survival (OS) of all patients by metformin. (A) OS (all patients) by metformin. Prolonged OS in metformin recipients versus non-recipients (hazard ratio [HR], 0.695; 95% confidence interval [CI], 0.509 to 0.948; p=0.022) (adjusted HR with performance, cancer extent, and weight loss [change in body mass index ≥ 1] during first-line therapy, 0.697; 95% CI, 0.491 to 0.990; p=0.044). (B) OS of diabetes mellitus (DM) treated with metformin surpassed that of other groups (non-DM or DM without metformin; p=0.029).

Table 1.

Status of DM and antidiabetic medication

Characteristic	Range	No. of patients (%)
DM status (n=349)	Concurrent DM	183 (52.4)
	Preexisting DM	160 (45.8)
	Remote-onset DM (≥ 2 yr)	87 (24.9)
	Recent-onset DM (< 2 yr)	73 (20.9)
	Subsequent DM	23 (6.6)
	Non-DM	166 (47.6)
Antidiabetic medication (n=183)	Yes	134 (73.2)
Antidiabetic medication (n=183)	No	49 (26.8)

DM, diabetes mellitus.

Table 2.

Clinical characteristics by DM status in advanced pancreatic cancer

Characteristic		Total (n=349)	DM vs. Non-DM		p-value^a)
Characteristic		Total (n=349)	DM (n=183)	Non-DM (n=166)	p-value^a)
Sex	Male	224 (64.2)	114 (62.3)	110 (66.3)	0.503
Sex	Female	125 (35.8)	69 (37.7)	56 (33.7)
Age (yr)	≥ 60	172 (49.3)	109 (59.6)	63 (38.0)	< 0.001
Age (yr)	< 60	177 (50.7)	74 (40.4)	103 (62.0)
ECOG PS	0-1	281 (80.5)	36 (19.7)	32 (19.3)	0.926
ECOG PS	≥ 2	68 (19.5)	147 (80.3)	134 (80.7)
Cancer extent	LAPC	66 (18.9)	37 (20.2)	29 (17.5)	0.585
Cancer extent	MPC	283 (81.1)	146 (79.8)	137 (82.5)
Initial BMI (kg/m²)	< 22.5	214 (62.0)	111 (61.0)	103 (63.2)	0.26
	22.5-24.9	89 (25.8)	44 (24.2)	45 (27.6)
	≥ 25.0	42 (12.2)	27 (14.8)	15 (9.2)
Weight loss, initial by BMI ≥ 1 kg/m²	Yes	193 (55.3)	110 (60.1)	83 (50.0)	0.067
Weight loss, initial by BMI ≥ 1 kg/m²	No	156 (44.7)	73 (39.9)	83 (50.0)
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	96 (33.1)	51 (33.1)	45 (33.1)	0.996
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	194 (66.9)	103 (66.9)	91 (66.9)
CA19-9	Elevated	282 (80.8)	149 (81.4)	133 (80.1)	0.787
CA19-9	Normal	67 (19.2)	34 (18.6)	33 (19.9)
Albumin	Decreased	82 (23.5)	46 (25.1)	36 (21.7)	0.452
Albumin	Normal	267 (76.5)	137 (74.9)	130 (78.3)
Response	Controlled	197 (56.4)	108 (59.0)	89 (53.6)	0.332
Response	Uncontrolled	152 (43.6)	75 (41.0)	77 (46.4)
Courses of chemotherapy	1	185 (53.0)	90 (49.2)	95 (57.2)	0.132
Courses of chemotherapy	≥ 2	164 (47.0)	93 (50.8)	71 (42.8)

Values are presented as number (%). DM, diabetes mellitus; ECOG PS, Eastern Cooperative Oncology Group performance status; LAPC, locally advanced pancreatic cancer; MPC, metastatic pancreatic cancer; BMI, body mass index; CA 19-9, cancer antigen 19-9.

^a) Fisher exact test.

Table 3.

Factors impacting overall survival (all patients)

Clinical factor		mOS (95% CI, mo)	Univariate analysis			Multivariate analysis
Clinical factor		mOS (95% CI, mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Sex	Male	7.2 (6.1-8.3)	1.044	0.826-1.319	0.719	-	-	-
Sex	Female	9.1 (7.5-10.7)	1			-
Age (yr)	≥ 60	7.2 (6.3-8.1)	1.137	0.912-1.417	0.255	-	-	-
Age (yr)	< 60	9.1 (7.7-10.5)	1			-
ECOG PS	≥ 2	6.6 (5.4-7.8)	1.411	1.075-1.852	0.013	1.230	0.894-1.692	0.203
ECOG PS	0-1	8.8 (7.6-10.0)	1			1
Cancer extent	MPC	7.2 (6.5-7.9)	1.809	1.352-2.420	< 0.001	1.792	1.313-2.445	< 0.001
Cancer extent	LAPC	12.8 (10.5-15.0)	1			1
DM	Yes	8.4 (6.8-10.0)	0.793	0.635-0.990	0.041	0.788	0.615-1.009	0.059
DM	No	7.5 (6.3-8.7)	1			1
Initial BMI (kg/m²)	< 22.5	7.3 (6.2-8.4)	1.289	0.989-1.679	0.06	-	-	-
	22.5-24.9	9.8 (8.6-11.0)	1		Reference	-		-
	≥ 25.0	6.7 (3.5-9.9)	1.119	0.758-1.651	0.572	-	-	-
Weight loss, initial by BMI ≥ 1 kg/m²	Yes	7.9 (6.6-9.1)	1.097	0.877-1.372	0.417	-	-	-
Weight loss, initial by BMI ≥ 1 kg/m²	No	8.0 (6.5-9.5)	1			-
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	8.2 (5.7-10.6)	1.347	1.036-1.752	0.026	1.270	0.970-1.661	0.082
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	9.3 (8.1-10.6)	1			1

mOS, median overall survival; CI, confidence interval; HR, hazard ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; MPC, metastatic pancreatic cancer; LAPC, locally advanced pancreatic cancer; DM, diabetes mellitus; BMI, body mass index.

^a) Cox proportional hazard model,

^b) Cox proportional hazard model adjusted with performance status, DM status, cancer extent, and weight loss during first-line therapy.

Table 4.

Patient survival by DM subsets

Clinical factor		No. (n=183)	mOS (95% CI, mo)	HR (95% CI)	p-value^a)
Recent-onset DM	Yes	73	9.8 (7.1-12.5)	0.789 (0.574-1.083)	0.142
Recent-onset DM	No	110	7.9 (6.2-9.5)	1
Antidiabetic medication	Yes	134	9.1 (7.0-11.2)	0.674 (0.472-0.962)	0.203
Antidiabetic medication	No	49	8.4 (6.6-10.2)	1
Metformin	Yes	56	11.0 (7.3-14.8)	0.693 (0.492-0.977)	0.036
Metformin	No	127	7.9 (6.0-9.7)	1
Sulfonylurea	Yes	62	9.9 (6.6-13.1)	0.894 (0.643-1.244)	0.507
Sulfonylurea	No	121	7.9 (6.2-9.5)	1
Insulin	Yes	43	7.4 (3.8-8.3)	0.782 (0.542-1.127)	0.187
Insulin	No	140	8.8 (7.3-10.4)	1

DM, diabetes mellitus; mOS, median overall survival; CI, confidence interval; HR, hazard ratio.

^a) Cox proportional hazard model.

Table 5.

Factors impacting overall survival (all patients)

Clinical factor		mOS (95% CI, mo)	Multivariate analysis
Clinical factor		mOS (95% CI, mo)	HR (95% CI)	p-value^a)
ECOG PS	≥ 2	6.6 (5.4-7.8)	1.224 (0.890-1.683)	0.215
ECOG PS	0-1	8.8 (7.6-10.0)	1
Cancer extent	MPC	7.2 (6.5-7.9)	1.703 (1.249-2.322)	0.001
Cancer extent	LAPC	12.8 (10.5-15.0)	1
Metformin	Yes	11.0 (7.3-14.8)	0.697 (0.491-1.990)	0.044
Metformin	No	7.8 (6.8-8.8)	1
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	8.2 (5.7-10.6)	1.257 (0.961-1.644)	0.095
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	9.3 (8.1-10.6)	1

^a) Cox proportional hazard model adjusted with performance status, cancer extent, metformin use, and weight loss during first-line therapy.

REFERENCES

1. Kris MG, Benowitz SI, Adams S, Diller L, Ganz P, Kahlenberg MS, et al. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010;28:5327–47. Article PubMed
2. Andre T, Balosso J, Louvet C, Gligorov J, Callard P, de Gramont A, et al. Adenocarcinoma of the pancreas. General characteristics. Presse Med. 1998;27:533–6. PubMed
3. Chiu CC, Huang CC, Chen YC, Chen TJ, Liang Y, Lin SJ, et al. Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan. Intern Med. 2013;52:939–46. Article PubMed
4. Kuuselo R, Savinainen K, Azorsa DO, Basu GD, Karhu R, Tuzmen S, et al. Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res. 2007;67:1943–9. Article PubMed
5. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005;65:9164–8. Article PubMed
6. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134:981–7. Article PubMed PMC
7. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92:2076–83. Article PubMed PMC
8. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95. Article PubMed PMC
9. Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008;134:95–101. Article PubMed PMC
10. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9:403–10. Article PubMed
11. Wakasugi H, Funakoshi A, Iguchi H. Clinical observations of pancreatic diabetes caused by pancreatic carcinoma, and survival period. Int J Clin Oncol. 2001;6:50–4. Article PubMed
12. Chu CK, Mazo AE, Goodman M, Egnatashvili V, Sarmiento JM, Staley CA, et al. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma. Ann Surg Oncol. 2010;17:502–13. Article PubMed
13. Mizuno S, Nakai Y, Isayama H, Takahara N, Miyabayashi K, Yamamoto K, et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology. 2013;13:285–9. Article PubMed
14. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482–8. Article PubMed PMC
15. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18:2905.Article PubMed PMC
16. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719–29. Article PubMed PMC
17. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73. Article PubMed
18. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469–80. Article PubMed
19. Hwang AL, Haynes K, Hwang WT, Yang YX. Metformin and survival in pancreatic cancer: a retrospective cohort study. Pancreas. 2013;42:1054–9. Article PubMed PMC
20. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Endocr Relat Cancer. 2015 Jan 8 [Epub]. http://dx.doi.org/10.1097/SLA.0000000000001086.Article
21. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer. 2012;19:F9–F26. Article PubMed
22. Hwang A, Narayan V, Yang YX. Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma: a retrospective cohort study. Cancer. 2013;119:404–10. Article PubMed
23. Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, et al. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015;33:29–35. Article PubMed PMC
24. Nakai Y, Isayama H, Sasaki T, Mizuno S, Sasahira N, Kogure H, et al. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas. 2013;42:202–8. Article PubMed
25. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10:423–33. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients
Xinzhe Zhu, Huaxiang Xu, Zhiwen Xiao, He Liu, Quanxing Ni, Xianjun Yu, Guopei Luo
Endocrine.2023; 79(2): 296. CrossRef
Influence of diabetes mellitus and effectiveness of metformin on hepatocellular carcinoma
Masafumi Ono, Koji Fujita, Kiyoyuki Kobayashi, Tsutomu Masaki
Hepatology Research.2023; 53(7): 579. CrossRef
Diabetes duration and weight loss are associated with onset age and remote metastasis of pancreatic cancer in patients with diabetes mellitus
Minglei Ma, Wei Li, Lingling Xu, Fan Ping, Huabing Zhang, Yuxiu Li
Journal of Diabetes.2022; 14(4): 261. CrossRef
Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma—Prevalence, Clinicopathological Variables, and Clinical Outcomes
Anna Badowska-Kozakiewicz, Marta Fudalej, Daria Kwaśniewska, Marek Durlik, Anna Nasierowska-Guttmejer, Agata Mormul, Emilia Włoszek, Aleksandra Czerw, Tomasz Banaś, Andrzej Deptała
Cancers.2022; 14(12): 2840. CrossRef
Prognostic value of metformin in cancers: An updated meta-analysis based on 80 cohort studies
Jing Yang, Hang Yang, Ling Cao, Yuzhen Yin, Ying Shen, Wei Zhu
Medicine.2022; 101(49): e31799. CrossRef
Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704
Danielle S. Bitterman, Kathryn A. Winter, Theodore S. Hong, Charles S. Fuchs, William F. Regine, Ross A. Abrams, Howard Safran, John P. Hoffman, Al B. Benson, Timothy Kasunic, Mary Mulcahy, James F. Strauss, Thomas DiPetrillo, Philip J. Stella, Yuhchyau C
International Journal of Radiation Oncology*Biology*Physics.2021; 109(1): 201. CrossRef
Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer
Ayşegül SAKİN, Suleyman SAHİN, Abdullah SAKİN, Muhammed ATCİ, Çağlayan GEREDELİ, Şener CİHAN
Journal of Surgery and Medicine.2021; 5(1): 17. CrossRef
Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
Yongde Luo, Xiaokun Li, Jianjia Ma, James L. Abbruzzese, Weiqin Lu
Cancers.2021; 13(4): 778. CrossRef
Repurposing metformin for the treatment of gastrointestinal cancer
Ademar Dantas Cunha Júnior, Arinilda Campos Bragagnoli, Felipe Osório Costa, José Barreto Campello Carvalheira
World Journal of Gastroenterology.2021; 27(17): 1883. CrossRef
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
Ondřej Fiala, Pavel Ostašov, Aneta Rozsypalová, Milan Hora, Ondrej Sorejs, Jan Šustr, Barbora Bendová, Ivan Trávníček, Jan Filipovský, Jindřich Fínek, Tomáš Büchler
Cancer Management and Research.2021; Volume 13: 4077. CrossRef
Magic of a Common Sugar Pill in Cancer: Can Metformin Raise Survival in Pancreatic Cancer Patients?
Mallika Gyawali, Nanditha Venkatesan, Opemipo D Ogeyingbo, Renu Bhandari, Rinky A Botleroo, Roaa Kareem, Rowan Ahmed, Abeer O Elshaikh
Cureus.2021;[Epub] CrossRef
Identification of Key Genes Involved in Diabetic Peripheral Neuropathy Progression and Associated with Pancreatic Cancer

Liumeng Jian, Guangda Yang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 463. CrossRef
Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus
Fumihiro Terasaki, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Yusuke Yamamoto, Ryo Ashida, Katsuhisa Ohgi, Katsuhiko Uesaka
Langenbeck's Archives of Surgery.2020; 405(3): 313. CrossRef
The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives
Bao Quoc Lam, Sushant K. Shrivastava, Anju Shrivastava, Sharmila Shankar, Rakesh K. Srivastava
Journal of Cellular and Molecular Medicine.2020; 24(14): 7706. CrossRef
Association between Metformin Use and Clinical Outcomes Following Pancreaticoduodenectomy in Patients with Type 2 Diabetes and Pancreatic Ductal Adenocarcinoma
Daegwang Yoo, Nayoung Kim, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Jaewoo Kwon, Yejong Park, Sarang Hong, Jong Woo Lee, Kyungyeon Hwang, Dakyum Shin, Eunyoung Tak, Song Cheol Kim
Journal of Clinical Medicine.2020; 9(6): 1953. CrossRef
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
Davide Brocco, Rosalba Florio, Laura De Lellis, Serena Veschi, Antonino Grassadonia, Nicola Tinari, Alessandro Cama
Cancers.2020; 12(7): 1849. CrossRef
Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival
Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte
International Journal of Environmental Research and Public Health.2020; 17(17): 6016. CrossRef
Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes
Yu-Qi Shi, Xiao-Chong Zhou, Peng Du, Min-Yue Yin, Lan Xu, Wen-Jie Chen, Chun-Fang Xu
Medicine.2020; 99(37): e21687. CrossRef
Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus
Adetunji T. Toriola, Suhong Luo, Theodore S. Thomas, Bettina F. Drake, Su-Hsin Chang, Kristen M. Sanfilippo, Kenneth R. Carson
Cancer Epidemiology, Biomarkers & Prevention.2020; 29(1): 169. CrossRef
Metformin and pancreatic cancer survival: Real effect or immortal time bias?
Min Wei, Yu Liu, Yongyi Bi, Zhi‐Jiang Zhang
International Journal of Cancer.2019; 145(7): 1822. CrossRef
The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs
Habibeh Mashayekhi‐Sardoo, Amir Hooshang Mohammadpour, Homa Nomani, Amirhossein Sahebkar
Journal of Cellular Physiology.2019; 234(11): 19339. CrossRef
The impact of diabetes mellitus on clinical outcomes following chemotherapy for the patients with pancreatic cancer: a meta-analysis
Jichun Ma, Jing Wang, Long Ge, Bo Long, Junqiang Zhang
Acta Diabetologica.2019; 56(10): 1103. CrossRef
Obesity and Pancreatic Cancer
Mu Xu, Xiaoman Jung, O. Joe Hines, Guido Eibl, Yijun Chen
Pancreas.2018; 47(2): 158. CrossRef
Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis
Muhammad S. Beg, Arjun Gupta, David Sher, Sadia Ali, Saad Khan, Ang Gao, Tyler Stewart, Chul Ahn, Jarett Berry, Eric M. Mortensen
American Journal of Clinical Oncology.2018; 41(8): 766. CrossRef
Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use
Philip J. Broadhurst, Andrew R. Hart
Digestive Diseases and Sciences.2018; 63(11): 2840. CrossRef
Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study
Kellam Harry, Yim Kein-Leong
Journal of Diabetes & Metabolic Disorders.2018; 17(2): 247. CrossRef
No association between metformin use and survival in patients with pancreatic cancer
Martine A. Frouws, Babs G. Sibinga Mulder, Esther Bastiaannet, Marjolein M.J. Zanders, Myrthe P.P. van Herk-Sukel, Eleonora M. de Leede, Bert A. Bonsing, J. Sven. D. Mieog, Cornelis J.H. Van de Velde, Gerrit-Jan Liefers
Medicine.2017; 96(10): e6229. CrossRef
Chloride intracellular channel 1 regulates the antineoplastic effects of metformin in gallbladder cancer cells
Yongchen Liu, Zheng Wang, Maolan Li, Yuanyuan Ye, Yi Xu, Yichi Zhang, Ruiyan Yuan, Yunpeng Jin, Yajuan Hao, Lin Jiang, Yunping Hu, Shili Chen, Fatao Liu, Yijian Zhang, Wenguang Wu, Yingbin Liu
Cancer Science.2017; 108(6): 1240. CrossRef
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
Xiaogang Li, Tong Li, Zhiqiang Liu, Shanmiao Gou, Chunyou Wang
Scientific Reports.2017;[Epub] CrossRef
The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis
Xun Cao, Yaopan Wu, Jing Wang, Kuiyuan Liu, Xin Wang
JNCI Cancer Spectrum.2017;[Epub] CrossRef
Association of elevated risk of pancreatic cancer in diabetic patients: A systematic review and meta-analysis
Jiaxin Tan, Yu You, Fei Guo, Jianhua Xu, Haisu Dai, Ping Bie
Oncology Letters.2017; 13(3): 1247. CrossRef
Pancreatic Carcinoma and Diabetes Mellitus
Laszlo Czako
Gastroenterology & Hepatology: Open Access.2017;[Epub] CrossRef
Association between metformin use and mortality in patients with type 2 diabetes mellitus and localized resectable pancreatic cancer: a nationwide population-based study in korea
Won Il Jang, Mi-Sook Kim, Shin Hee Kang, Ae Jung Jo, Yun Jung Kim, Ha Jin Tchoe, Chan Mi Park, Hyo Jeong Kim, Jin A Choi, Hyung Jin Choi, Eun-Kyung Paik, Young Seok Seo, Hyung Jun Yoo, Jin-Kyu Kang, Chul Ju Han, Yeon Ju Kim, Sang Beom Kim, Min Jung Ko
Oncotarget.2017; 8(6): 9587. CrossRef
Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis
Ping-Ting Zhou, Bo Li, Fu-Rao Liu, Mei-Chao Zhang, Qian Wang, Yan-Yan Li, Ci Xu, Yuan-Hua Liu, Yuan Yao, Dong Li
Oncotarget.2017; 8(15): 25242. CrossRef
Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis
Yi-Wei Dong, Yan-Qiang Shi, Li-Wen He, Xi-Yu Cui, Pei-Zhu Su
Oncotarget.2017; 8(33): 55478. CrossRef
Prognostic significance of anti-diabetic medications in pancreatic cancer: A meta-analysis
Dong-Chu Zhou, Hui Gong, Chong-Qing Tan, Jian-Quan Luo
Oncotarget.2017; 8(37): 62349. CrossRef
Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: A meta-analysis
Wenxiu Xin, Luo Fang, Qilu Fang, Xiaowei Zheng, Ping Huang
Molecular and Clinical Oncology.2017;[Epub] CrossRef
Obesity and Cancer: An Angiogenic and Inflammatory Link
Dai Fukumura, Joao Incio, Ram C. Shankaraiah, Rakesh K. Jain
Microcirculation.2016; 23(3): 191. CrossRef
Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification
Archana Bhaw-Luximon, Dhanjay Jhurry
Journal of Cancer Research and Clinical Oncology.2016; 142(10): 2159. CrossRef
Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer
Marcelo Cerullo, Faiz Gani, Sophia Y. Chen, Joe Canner, Timothy M. Pawlik
Journal of Gastrointestinal Surgery.2016; 20(9): 1572. CrossRef
Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study
Gianpaolo Balzano, Erica Dugnani, Alessandra Gandolfi, Marina Scavini, Valentina Pasquale, Francesca Aleotti, Daniela Liberati, Gaetano Di Terlizzi, Giovanna Petrella, Michele Reni, Claudio Doglioni, Emanuele Bosi, Massimo Falconi, Lorenzo Piemonti, Surin
PLOS ONE.2016; 11(11): e0166008. CrossRef
Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study
Issam Makhoul, Abdulraheem Yacoub, Eric Siegel
SAGE Open Medicine.2016;[Epub] CrossRef
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
Yuqi Shi, Zhilong He, Zhenyu Jia, Chunfang Xu
Molecular Medicine Reports.2016; 14(4): 2921. CrossRef
Diabetes mellitus and metformin in hepatocellular carcinoma
Koji Fujita, Hisakazu Iwama, Hisaaki Miyoshi, Joji Tani, Kyoko Oura, Tomoko Tadokoro, Teppei Sakamoto, Takako Nomura, Asahiro Morishita, Hirohito Yoneyama, Tsutomu Masaki
World Journal of Gastroenterology.2016; 22(27): 6100. CrossRef
High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers
Chen Roujun, Yi Yanhua, Li Bixun
F1000Research.2016; 5: 1397. CrossRef
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial
Michele Reni, Erica Dugnani, Stefano Cereda, Carmen Belli, Gianpaolo Balzano, Roberto Nicoletti, Daniela Liberati, Valentina Pasquale, Marina Scavini, Paola Maggiora, Valeria Sordi, Vito Lampasona, Domenica Ceraulo, Gaetano Di Terlizzi, Claudio Doglioni,
Clinical Cancer Research.2016; 22(5): 1076. CrossRef
Can metformin improve ‘the tomorrow’ of patients treated for oesophageal cancer?
L. Van De Voorde, L. Janssen, R. Larue, R. Houben, J. Buijsen, M. Sosef, B. Vanneste, M.-C. Schraepen, M. Berbée, P. Lambin
European Journal of Surgical Oncology (EJSO).2015; 41(10): 1333. CrossRef
Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2
Sang Hoon Lee, Sang Hyun Yoon, Hee Seung Lee, Moon Jae Chung, Jeong Youp Park, Seung Woo Park, Si Young Song, Jae Bock Chung, Seungmin Bang
Digestive and Liver Disease.2015;[Epub] CrossRef
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling
Xinqun Chai, Hongpeng Chu, Xuan Yang, Yuanpu Meng, Pengfei Shi, Shanmiao Gou
Scientific Reports.2015;[Epub] CrossRef
Obesity and cancer, a case for insulin signaling
Y Poloz, V Stambolic
Cell Death & Disease.2015; 6(12): e2037. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

Cancer Res Treat. 2016;48(1):171-179. Published online March 13, 2015

DOI: https://doi.org/10.4143/crt.2014.292

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
Electronic Supplementary Material
NOTES
REFERENCES

Impact of Social Support during Diagnosis and Treatment on Disease Progression in Young Patients with Breast Cancer: A Prospective Cohort Study

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

Fig. 1. Overall survival (OS) of all patients by diabetes mellitus (DM) status. Kaplan-Meier estimates, demonstrating positive association between DM and OS (hazard ratio, 0.793; 95% confidence interval, 0.635 to 0.990; p=0.041, log-rank test). mOS, median OS.

Fig. 2. Overall survival of diabetes mellitus (DM) patients. (A) Recent-onset DM, not having significantly prolonged overall survival (OS) (vs. other DM subsets, including remote-onset DM and subsequent DM; hazard ratio [HR], 0.789; 95% confidence interval [CI], 0.574 to 1.083; p=0.142). (B) OS prolongation in metformin recipients vs non-recipients (HR, 0.693; 95% CI, 0.492 to 0.977; p=0.036). mOS, median OS.

Fig. 3. Overall survival (OS) of all patients by metformin. (A) OS (all patients) by metformin. Prolonged OS in metformin recipients versus non-recipients (hazard ratio [HR], 0.695; 95% confidence interval [CI], 0.509 to 0.948; p=0.022) (adjusted HR with performance, cancer extent, and weight loss [change in body mass index ≥ 1] during first-line therapy, 0.697; 95% CI, 0.491 to 0.990; p=0.044). (B) OS of diabetes mellitus (DM) treated with metformin surpassed that of other groups (non-DM or DM without metformin; p=0.029).

Fig. 1.

Fig. 2.

Fig. 3.

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy

Characteristic	Range	No. of patients (%)
DM status (n=349)	Concurrent DM	183 (52.4)
	Preexisting DM	160 (45.8)
	Remote-onset DM (≥ 2 yr)	87 (24.9)
	Recent-onset DM (< 2 yr)	73 (20.9)
	Subsequent DM	23 (6.6)
	Non-DM	166 (47.6)
Antidiabetic medication (n=183)	Yes	134 (73.2)
Antidiabetic medication (n=183)	No	49 (26.8)

Characteristic		Total (n=349)	DM vs. Non-DM		p-value^a)
Characteristic		Total (n=349)	DM (n=183)	Non-DM (n=166)	p-value^a)
Sex	Male	224 (64.2)	114 (62.3)	110 (66.3)	0.503
Sex	Female	125 (35.8)	69 (37.7)	56 (33.7)
Age (yr)	≥ 60	172 (49.3)	109 (59.6)	63 (38.0)	< 0.001
Age (yr)	< 60	177 (50.7)	74 (40.4)	103 (62.0)
ECOG PS	0-1	281 (80.5)	36 (19.7)	32 (19.3)	0.926
ECOG PS	≥ 2	68 (19.5)	147 (80.3)	134 (80.7)
Cancer extent	LAPC	66 (18.9)	37 (20.2)	29 (17.5)	0.585
Cancer extent	MPC	283 (81.1)	146 (79.8)	137 (82.5)
Initial BMI (kg/m²)	< 22.5	214 (62.0)	111 (61.0)	103 (63.2)	0.26
	22.5-24.9	89 (25.8)	44 (24.2)	45 (27.6)
	≥ 25.0	42 (12.2)	27 (14.8)	15 (9.2)
Weight loss, initial by BMI ≥ 1 kg/m²	Yes	193 (55.3)	110 (60.1)	83 (50.0)	0.067
Weight loss, initial by BMI ≥ 1 kg/m²	No	156 (44.7)	73 (39.9)	83 (50.0)
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	96 (33.1)	51 (33.1)	45 (33.1)	0.996
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	194 (66.9)	103 (66.9)	91 (66.9)
CA19-9	Elevated	282 (80.8)	149 (81.4)	133 (80.1)	0.787
CA19-9	Normal	67 (19.2)	34 (18.6)	33 (19.9)
Albumin	Decreased	82 (23.5)	46 (25.1)	36 (21.7)	0.452
Albumin	Normal	267 (76.5)	137 (74.9)	130 (78.3)
Response	Controlled	197 (56.4)	108 (59.0)	89 (53.6)	0.332
Response	Uncontrolled	152 (43.6)	75 (41.0)	77 (46.4)
Courses of chemotherapy	1	185 (53.0)	90 (49.2)	95 (57.2)	0.132
Courses of chemotherapy	≥ 2	164 (47.0)	93 (50.8)	71 (42.8)

Clinical factor		mOS (95% CI, mo)	Univariate analysis			Multivariate analysis
Clinical factor		mOS (95% CI, mo)	HR	95% CI	p-value^a)	HR	95% CI	p-value^b)
Sex	Male	7.2 (6.1-8.3)	1.044	0.826-1.319	0.719	-	-	-
Sex	Female	9.1 (7.5-10.7)	1			-
Age (yr)	≥ 60	7.2 (6.3-8.1)	1.137	0.912-1.417	0.255	-	-	-
Age (yr)	< 60	9.1 (7.7-10.5)	1			-
ECOG PS	≥ 2	6.6 (5.4-7.8)	1.411	1.075-1.852	0.013	1.230	0.894-1.692	0.203
ECOG PS	0-1	8.8 (7.6-10.0)	1			1
Cancer extent	MPC	7.2 (6.5-7.9)	1.809	1.352-2.420	< 0.001	1.792	1.313-2.445	< 0.001
Cancer extent	LAPC	12.8 (10.5-15.0)	1			1
DM	Yes	8.4 (6.8-10.0)	0.793	0.635-0.990	0.041	0.788	0.615-1.009	0.059
DM	No	7.5 (6.3-8.7)	1			1
Initial BMI (kg/m²)	< 22.5	7.3 (6.2-8.4)	1.289	0.989-1.679	0.06	-	-	-
	22.5-24.9	9.8 (8.6-11.0)	1		Reference	-		-
	≥ 25.0	6.7 (3.5-9.9)	1.119	0.758-1.651	0.572	-	-	-
Weight loss, initial by BMI ≥ 1 kg/m²	Yes	7.9 (6.6-9.1)	1.097	0.877-1.372	0.417	-	-	-
Weight loss, initial by BMI ≥ 1 kg/m²	No	8.0 (6.5-9.5)	1			-
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	8.2 (5.7-10.6)	1.347	1.036-1.752	0.026	1.270	0.970-1.661	0.082
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	9.3 (8.1-10.6)	1			1

Clinical factor		No. (n=183)	mOS (95% CI, mo)	HR (95% CI)	p-value^a)
Recent-onset DM	Yes	73	9.8 (7.1-12.5)	0.789 (0.574-1.083)	0.142
Recent-onset DM	No	110	7.9 (6.2-9.5)	1
Antidiabetic medication	Yes	134	9.1 (7.0-11.2)	0.674 (0.472-0.962)	0.203
Antidiabetic medication	No	49	8.4 (6.6-10.2)	1
Metformin	Yes	56	11.0 (7.3-14.8)	0.693 (0.492-0.977)	0.036
Metformin	No	127	7.9 (6.0-9.7)	1
Sulfonylurea	Yes	62	9.9 (6.6-13.1)	0.894 (0.643-1.244)	0.507
Sulfonylurea	No	121	7.9 (6.2-9.5)	1
Insulin	Yes	43	7.4 (3.8-8.3)	0.782 (0.542-1.127)	0.187
Insulin	No	140	8.8 (7.3-10.4)	1

Clinical factor		mOS (95% CI, mo)	Multivariate analysis
Clinical factor		mOS (95% CI, mo)	HR (95% CI)	p-value^a)
ECOG PS	≥ 2	6.6 (5.4-7.8)	1.224 (0.890-1.683)	0.215
ECOG PS	0-1	8.8 (7.6-10.0)	1
Cancer extent	MPC	7.2 (6.5-7.9)	1.703 (1.249-2.322)	0.001
Cancer extent	LAPC	12.8 (10.5-15.0)	1
Metformin	Yes	11.0 (7.3-14.8)	0.697 (0.491-1.990)	0.044
Metformin	No	7.8 (6.8-8.8)	1
Weight loss, during first-line, by BMI ≥ 1 kg/m²	Yes	8.2 (5.7-10.6)	1.257 (0.961-1.644)	0.095
Weight loss, during first-line, by BMI ≥ 1 kg/m²	No	9.3 (8.1-10.6)	1

Table 1. Status of DM and antidiabetic medication

DM, diabetes mellitus.

Table 2. Clinical characteristics by DM status in advanced pancreatic cancer

Fisher exact test.

Table 3. Factors impacting overall survival (all patients)

Cox proportional hazard model,

Cox proportional hazard model adjusted with performance status, DM status, cancer extent, and weight loss during first-line therapy.

Table 4. Patient survival by DM subsets

DM, diabetes mellitus; mOS, median overall survival; CI, confidence interval; HR, hazard ratio.

Cox proportional hazard model.

Table 5. Factors impacting overall survival (all patients)

Cox proportional hazard model adjusted with performance status, cancer extent, metformin use, and weight loss during first-line therapy.